Efficacy, Safety and Pharmacokinetic Study of Intravenous Clonidine Versus Midazolam for Sedation in Paediatric Patients

Sedation in Intensive Care Clinical Trial

— CloSed1  

Official title:

A Double Blind, Randomised, Multicentre, Active Controlled, Parallel-group, Phase III Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of Intravenous Clonidine (Hydrochloride) Compared to Midazolam for Sedation in Children From Birth to Less Than 18 Years of Age

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02509273
• Other study ID #: CLON01
• Secondary ID: 2014-003582-24
• Status: Terminated
• Phase: Phase 3
• Start date: May 2016
• Est. completion date: October 22, 2018

Study information

• Verified date: January 2019
• Source: University of Erlangen-Nürnberg Medical School
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Closed1 aims to compare the efficacy, safety and pharmacokinetics of clonidine (hydrochloride) to midazolam in the sedation of ventilated children and adolescents (0-18 years) admitted to a paediatric intensive care unit (PICU) and requiring mechanical ventilation and sedation for at least 24 hours.

In particular, the proportion of subjects with sedation failure at the maximum possible dose (defined within the study protocol) will be measured. Additionally, the safety and tolerability (including withdrawal effects) of clonidine compared to midazolam will be evaluated. A pharmacokinetic-pharmacodynamic relationship of clonidine for sedation in PICU will be established. Genetic polymorphisms of clinical relevance affecting pharmacokinetics, pharmacodynamics and metabolism will be also identified.

Ad hoc paediatric parenteral formulations of clonidine hydrochloride and midazolam will be manufactured. At least 300 subjects will be enrolled from study centres in five European member countries (Czech Republic, Germany, Italy, the Netherlands, and Sweden).

The clinical study will enrol critically ill paediatric patients who require mechanical ventilation and sedation.

Subjects will be closely followed using standard PICU monitoring of vital functions (continuous assessment of heart rate and peripheral arterial oxygen saturation, intermittent assessment of systolic and diastolic blood pressure), intermittent assessment of pain and depth of sedation, documentation of parameters of mechanical ventilation and intermittent arterial blood gas analysis.

The study will be conducted in compliance with the study protocol, Good Clinical Practice (ICH-GCP) and the applicable regulatory requirement(s). In addition, qualified PICU staff will be monitoring subjects around the clock, thus minimising reaction time in case of alarms or deterioration of clinical parameters.

This project has received funding from the European Union's Seventh Framework Programme for research, technological development and demonstration under grant agreement n° 602453.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 28
• Est. completion date: October 22, 2018
• Est. primary completion date: October 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 18 Years

Eligibility

Inclusion Criteria:

• Male or Female

• Aged from birth (=34 weeks gestational age [GA]) to <17 years, 11 months, 1 week old

• Admitted or expected to be admitted (post-operatively) to PICU

• Existing or expected indication for invasive or non-invasive ventilation (except Continuous Positive Airway Pressure, CPAP)

• Anticipated need for continuous sedation for at least 24 hours

• Informed consent (or deferred consent) obtained from the subject's parent(s) or legal guardian(s)

• Where applicable, assent obtained from the subject to participate in the clinical trial

Exclusion Criteria:

• Body weight less than 1500 g

• Gestational age [GA] of <34 weeks

• Body weight 3 kg or less AND aged 28 days or older

• Body weight less than 10 kg AND aged 2 years old or older

• Body weight greater than 85 kg

• Subjects who will be 18 years old in less than 3 weeks

• Known hypersensitivity to the IMP (clonidine) or comparator (midazolam), or Non Investigational Medicinal Product (morphine, propofol) or any of their formulation ingredients and their rescue medication

• Subjects anticipated to be treated with forbidden concomitant medications during IMP administration

• Subjects less than 24 hours post-resuscitation

• Subjects who have been under sedation for more than 72 hours immediately prior to assessment

• Subjects currently being treated with Extra Corporeal Membrane Oxygenation (ECMO)

• Subjects with treatment-induced whole body hypothermia

• Subjects with severe organ insufficiencies

• Subjects whose condition is assessed by the investigator to have an effect on the level of consciousness which impairs the assessment of sedation (COMFORT-B/NISS)

• Subjects with phaeochromocytoma

• Subjects with severe bradyarrhythmia resulting from either sick-sinus syndrome or atrioventricular (AV) block of 2nd or 3rd degree

• Known arterial hypertension requiring chronic treatment in medical history

• Females who are pregnant, lactating or planning to become pregnant or who return a positive result to a urine pregnancy test (a dipstick and serum pregnancy test will be performed at the screening visit).

• Employee or direct relative of an employee or any member of the study site staff or the Sponsor/ study management staff (applies to subject and/ or subject's parent(s)

• Participation in a clinical intervention study using drugs within the last 3 weeks

• Previous participation in this clinical study at any time

• Parent(s)/ legal guardian(s) decline to give informed consent. If parent(s)/ legal guardian(s) are not present

Related Conditions & MeSH terms

• Sedation in Intensive Care

Intervention

Drug:
• Clonidine

• Midazolam

Locations

Country	Name	City	State
Czechia	Univerzita Karlova v Praze	Prague
Estonia	Tallinn Children`s Hospital	Tallinn
Germany	University of Erlangen-Nürnberg Medical School	Erlangen
Germany	Diakonie Neuendettelsau - Cnopf'sche Kinderklinik Nürnberg	Nürnberg
Italy	Azienda Ospedaliero Universitaria Policlinico di Bari	Bari
Italy	ARNAS Civico Di Cristina Benfratelli	Palermo
Italy	Bambino Gesù Hospital and Research Institute	Rome
Netherlands	Erasmus Medical Center	Rotterdam	Zuid-Holland
Spain	Hospital Universitario 12 de Octubre	Madrid
Sweden	Karolinska Institutet	Stockholm

Sponsors (13)

Lead Sponsor	Collaborator
University of Erlangen-Nürnberg Medical School	ARNAS Civico Di Cristina Benfratelli, Bambino Gesù Hospital and Research Institute, Erasmus Medical Center, European Commission, Gianni Benzi Pharmacological Research Foundation, Karolinska Institutet, Servicio Madrileño de Salud, Madrid, Spain, Therakind Ltd, University College, London, University of Tartu, Univerzita Karlova v Praze, Vereniging Samenwerkende Ouder- En Patientenorganisaties

Countries where clinical trial is conducted

Czechia,  Estonia,  Germany,  Italy,  Netherlands,  Spain,  Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sedation failure	measured by pain score Numerical Rating Scale (NRS), sedation score COMFORT-B and sedation score Nurse's Interpretation of Sedation (NISS)	= 7 days
Secondary	Pharmacokinetics/Pharmacodynamics (PKPD) modeling (measured by plasma concentrations and sedation score results (COMFORT-B)	measured by plasma concentrations and sedation score results (COMFORT-B)	= 7 days treatment period
Secondary	Safety assessment (number of patients with adverse events)	measured by number of patients with adverse events	= 21 ± 2 days (treatment period, completion visit, post dose monitoring and follow-up visit) in all subjects
Secondary	Extent of withdrawal effects	measured by score Sophia Observation Withdrawal Symptoms-Paediatric Delirium (SOS-PD)	post dose = 1 day, = 5 days
Secondary	Extent of rebound hypertension	measured by blood pressure assessment for at least 72 hours after IMP cessation	post dose = 3 days, = 5 days
Secondary	Percentage of respiratory depression per group	Number of reintubations / number extubation failures ratio %	during re-intubation apnoea in treatment period (= 7 days), post dose monitoring every 24 hours up to 10 days
Secondary	Neurodevelopment (Bayley Scales of Infant Development, Second Edition (Bayley-II) score)	Bayley Scales of Infant Development, Second Edition (Bayley-II) score	1 year (in neonates only)
Secondary	Pharmacogenomic assessment (measured by plasma concentrations and candidate gene polymorphisms/genotyping)	measured by plasma concentrations and candidate gene polymorphisms/genotyping	On 1 day of treatment period (=7 days) only